Apogee Therapeutics (APOG) Shares Drop 11% Despite Positive Phase 2 Atopic Dermatitis Data

Shares of Apogee Therapeutics Inc. (APOG) fell 11% on May 27, 2026, even as the biotech reported positive results from a Phase 2 trial of its experimental treatment zumilokibart in atopic dermatitis. The decline erased gains from earlier in the week, suggesting investors had priced in stronger efficacy data to compete in the crowded inflammatory disease market. Apogee said the trial met its primary endpoint, showing a statistically significant improvement in clearing skin lesions compared to placebo. The company plans to advance the drug into Phase 3 studies. However, analysts noted the magnitude of improvement, while positive, might not differentiate sharply from established therapies like Sanofi’s Dupixent. The drop came despite broader market stability. Apogee had been trading near a 52-week high before the announcement, signaling elevated expectations. As of publication time, shares were at $28.40, down from a prior close of $31.91.